Re: Elan - market will not ignore bapineuzumab expectations
Building a sales force to sell $1.5b of product is how you build value in a company.
Ingram is clearly nothing to Elan: same old same old is the order of the day (only even more so.) The proxy questions were insulting to all Elan shareholders, including non-executive FTEs of Elan (but not including the overcompensated, underperforming executive team and BOD.)
If Ingram represented real management then we would have 7 directors, a much leaner management structure, and would be building operating infrastructure. We don't, we don't, and we aren't.